CJC-1295 vs GHRP-2
Side-by-side comparison of CJC-1295, GHRP-2 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone | GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | GHRH Analogue | Growth Hormone Releasing Peptide (GHRP) |
| Amino acids | 29 | 6 |
| Molecular weight | 3,368.9 Da | 817.9 Da |
| Half-life | 30 min (without DAC) / 7–8 days (with DAC) | ~1–2 hours |
| Route(s) | Subcutaneous, Intramuscular | Subcutaneous, Intramuscular, Intranasal |
| Mechanism & Research | ||
| Primary mechanism | CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi… | GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se… |
| Research status | Research Compound | Research Compound |
| Evidence summary | Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs. | GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class. |
| Protocol & Dosing | ||
| Typical dose | 100–200 mcg (without DAC); 2mg every 2 weeks (with DAC) | 100–200 mcg per injection |
| Frequency | 2–3x daily (without DAC); biweekly (with DAC) | 2–3x daily |
| Duration | 8–16 weeks | 8–12 weeks |
| Timing | Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly. | Fasted state; 2+ hours post-meal |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Ipamorelin, Sermorelin, GHRP-2, Tesamorelin | Ipamorelin, CJC-1295, GHRP-6, Hexarelin |
| Full profile | Read full CJC-1295 profile → | Read full GHRP-2 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.